Caris Life Sciences, Inc. (CAI)

Caris Life Sciences will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Caris Life Sciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	452.5	412.26	306.13
Revenue Growth (YoY)	-	34.67%	-
Cost of Revenue	-	233.48	216.82
Gross Profit	209.73	178.78	89.31
Selling, General & Admin	-	321.99	291.98
Research & Development	-	113.92	116.88
Operating Expenses	-	435.9	408.86
Operating Income	-222.85	-257.12	-319.55
Interest Expense / Income	47.66	42.9	20.35
Other Expense / Income	2.93	-18.14	1.51
Pretax Income	-371.16	-378.26	-462.53
Net Income	-273.44	-281.89	-341.42
Net Income Common	-371.16	-378.26	-462.53
Free Cash Flow	-212.01	-253.64	-298.42
Gross Margin	46.35%	43.37%	29.17%
Operating Margin	-49.25%	-62.37%	-104.38%
Profit Margin	-82.02%	-91.75%	-151.09%
Free Cash Flow Margin	-46.85%	-61.52%	-97.48%
EBITDA	-180.12	-183.02	-266.68
EBITDA Margin	-39.81%	-44.39%	-87.11%
Depreciation & Amortization	45.66	55.97	54.38
EBIT	-225.78	-238.99	-321.06
EBIT Margin	-49.90%	-57.97%	-104.88%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).